Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates

Executive Summary

The UK's health care cost-assessment body finds Gilead's newest combo, Epclusa, cost-effective in most HCV settings. J&J/Achillion now have 12-week SVR data for six-week treatment regimen, and AbbVie builds support for an eight-week regimen for Viekirax.

Advertisement

Related Content

J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV
NICE Backs Hep C Drug Zepatier After Merck Offers Price Discount
Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register